AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
173.60
+1.10 (+0.64%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close172.50
Open172.65
Bid173.64 x 800
Ask173.81 x 900
Day's Range172.65 - 174.62
52 Week Range114.27 - 190.36
Volume3,362,757
Avg. Volume3,287,823
Market Cap56.958B
Beta (3Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-25.50
Earnings DateNov 5, 2019
Forward Dividend & Yield2.96 (1.74%)
Ex-Dividend Date2019-08-12
1y Target Est183.40
Trade prices are not sourced from all markets
  • Reuters

    UPDATE 6-Opioid settlement talks fail, landmark trial expected Monday

    A landmark trial over the U.S. opioid epidemic is on track to begin on Monday after drug companies and local governments failed to agree on a settlement on Friday that had been expected to be valued at around $50 billion. Top executives of the largest U.S. drug distributors and drugmaker Teva Pharmaceutical Industries Ltd left a Cleveland courthouse on Friday and lawyers for states and thousands of local governments said there was no agreement. Paul Hanly, a lawyer for local governments that brought the bulk of the thousands of lawsuits stemming from the addiction crisis, said his team "fully expect" a trial to begin Monday.

  • Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow
    Zacks

    Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

    FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

  • Reuters

    Judge's unorthodox approach has huge opioid settlement within reach

    From the start of the sprawling U.S. litigation seeking to hold drugmakers and distributors liable for the country's opioid epidemic, Judge Dan Polster has made one thing clear: he never wanted a trial. On Friday, Polster will make his most dramatic bid yet to avoid a landmark trial that is scheduled to start on Monday. The federal judge has summoned the top executives from several large healthcare companies to his Cleveland court to try to hammer out a settlement that could be worth around $50 billion.

  • PR Newswire

    Allergan to Report Third Quarter 2019 Financial Results

    DUBLIN , Oct. 17, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release third quarter 2019 financial results on Tuesday, November 5, 2019 , prior to the open of U.S. financial markets. ...

  • Editas Inks Deal for Gene Editing Neurological Disease Drugs
    Zacks

    Editas Inks Deal for Gene Editing Neurological Disease Drugs

    Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.

  • 'High-level dope dealers': Democratic candidates sound off on big pharma
    Yahoo Finance

    'High-level dope dealers': Democratic candidates sound off on big pharma

    Democratic candidates like Kamala Harris and Amy Klobuchar criticized big pharma companies for their role in the opioid crisis.

  • Allergan (AGN) Shareholders Approve Acquisition by AbbVie
    Zacks

    Allergan (AGN) Shareholders Approve Acquisition by AbbVie

    Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

  • Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors
    Zacks

    Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors

    Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.

  • Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
    Zacks

    Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

    Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

  • PR Newswire

    Allergan Shareholders Approve Proposed Acquisition by AbbVie

    Allergan plc (AGN) (the "Company" or "Allergan") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Allergan by AbbVie Inc ("AbbVie"). As described below, more than 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the "Court Meeting") and at an extraordinary general meeting of shareholders (the "EGM") were in favor of the transaction, representing (in each case) approximately 68.6 percent of the shares outstanding and eligible to be voted at each of the Allergan shareholder meetings held on October 14, 2019 in Dublin, Ireland. "On behalf of Allergan's Board of Directors and executive team, I would like to thank our shareholders for their overwhelming support of the proposed combination with AbbVie," said Brent Saunders, Chairman and CEO of Allergan.

  • PR Newswire

    Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

    DUBLIN, Oct. 11, 2019 /PRNewswire/ -- Allergan plc, (AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (MOLN.SW), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced two-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with neovascular (wet) age-related macular degeneration (nAMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab.

  • Wet AMD Space in Focus: New Drug Approvals & Key Advancements
    Zacks

    Wet AMD Space in Focus: New Drug Approvals & Key Advancements

    The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

  • PR Newswire

    On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living

    DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced a national education campaign called My Glaucoma. The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment regimen that fits their lifestyle. The resources available on www.MyGlaucoma.com are supported by a new survey of patients living with glaucoma and eye doctors, conducted in collaboration with Glaucoma Research Foundation (GRF), that found more than 75 percent of patients worry about vision loss because of the disease, but nearly half consider glaucoma to be only somewhat or not serious.

  • PR Newswire

    Allergan Expands REFRESH® Portfolio With New REFRESH® RELIEVA™ Lubricant Eye Drop Product Line

    - A Trifecta of Relief Formulated with HydroCell™ Technology Offers New Artificial Tear Options for Patients Suffering from Eye Dryness - DUBLIN , Oct. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), ...

  • Here Is Hedge Funds’ 22nd Most Popular Stock Pick
    Insider Monkey

    Here Is Hedge Funds’ 22nd Most Popular Stock Pick

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]

  • Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates
    Investor's Business Daily

    Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates

    Pharma companies Allergan, Bristol-Myers Squibb and Zoetis could top the Street's third-quarter earnings expectations, an analyst said Thursday. But he only expects Zoetis sales to beat.

  • PR Newswire

    INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of the Following Merger

    Chardan Heathcare Acquisition Corp. (CHAC) related to its combination with BiomX Ltd. Pursuant to the terms of the Merger Agreement, BiomX's securityholders will receive an aggregate of 16,625,000 Chardan shares. As a result of the Proposed Transaction, Chardan's public stockholders will only own approximately 20% of Chardan's stock. Click here for more information: https://www.monteverdelaw.com/case/chardan-healthcare-acquisition-corp.  It is free and there is no cost or obligation to you. Restoration Robotics, Inc (HAIR) related to its combination with Venus Concept Ltd. Pursuant to the terms of the Merger Agreement, each share of Venus Concept will be converted into the right to receive 8.6506 shares of Restoration Robotics common stock.

  • J&J Settles Ahead of Multi-District Opioid Trial, Stock Up
    Zacks

    J&J Settles Ahead of Multi-District Opioid Trial, Stock Up

    J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.

  • AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
    Investor's Business Daily

    AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?

    AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

  • PR Newswire

    Allergan to Showcase Late-Stage Data in Age-Related Macular Degeneration and Glaucoma at American Academy of Ophthalmology Annual Meeting

    - Presentations include a late-breaking Abicipar abstract and topline Phase 3 results of Bimatoprost SR - DUBLIN , Oct. 3, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical ...

  • Pharma Giant J&J Avoids Opioid Trial In Ohio With $20.4 Million Payout
    Investor's Business Daily

    Pharma Giant J&J Avoids Opioid Trial In Ohio With $20.4 Million Payout

    Johnson & Johnson stock bounded higher Wednesday after the Dow Jones pharmaceutical company settled claims out of Ohio that its misleading marketing led to two counties' opioid crises.

  • Allergan (AGN) Stock Moves -1.09%: What You Should Know
    Zacks

    Allergan (AGN) Stock Moves -1.09%: What You Should Know

    In the latest trading session, Allergan (AGN) closed at $166.46, marking a -1.09% move from the previous day.

  • 5 Most Shorted Sectors in 2019
    Investopedia

    5 Most Shorted Sectors in 2019

    Short interest in domestic equities, mutual funds and ETFs has risen to $905 billion this year, and the Health Care sector has seen the greatest increase in short exposure since the start of the year.

  • IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
    Zacks

    IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA

    IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.